EGFR and breast carcinoma: Lapatinib (Tykerb /Tyverb) is a dual tyrosine kinase inhibitor which interrupts the HER2/neu receptor (human EGFR type 2) and epidermal growth factor receptor (EGFR) signaling and it is used to treat HER2-positive breast cancers [18,19].